What This Site Is - and Is Not - Nexaph Reviews
NexaphReviews.com is an independent, unaffiliated review and information website. We are not Nexaph, we are not a dealer or reseller, we sell nothing, and we accept no money from any vendor. What we do is summarize publicly available community discussion, separate anecdote from published evidence, and teach the literacy skills this market punishes buyers for lacking.
Trademark Notice: This is an independent, unaffiliated review website. We are NOT affiliated, endorsed, sponsored, or connected in any way with Nexaph. All trademarks belong to their respective owners. This site only provides user-submitted public information and third-party reviews for educational reference.
Nexaph Reviews Start Here
What Is Nexaph?
The starting point: what the name refers to and what is actually verifiable.
Is Nexaph Legit?
No verdicts - a legitimacy checklist you can apply to any vendor.
Retatrutide Reviews
What public user reports discuss, and how to read them critically.
Side Effects
Published trial data vs. community anecdote, clearly separated.
What Happened to Nexaph?
Status rumors, their usual causes, and how to verify them.
Where to Buy?
The careful answer: we sell nothing and recommend no seller.
Nexaph Reviews From the Science Blog
What Is Retatrutide? The Triple Agonist Explained
A plain-language explainer of retatrutide: how the GIP/GLP-1/glucagon triple agonist works, what Phase 2 trials reported, and why it is still investigational.
GLP-1 Agonists Explained: How the Drug Class Works
GLP-1 agonists explained: what the hormone does, how agonist medicines mimic it, which products are approved, and what that means for grey-market versions.
What Are Peptides? A Beginner’s Guide
Peptides explained for beginners: what they are, how they relate to proteins, how they are made, and why some become medicines while others stay research chemicals.
The GLP-1 Landscape at a Glance
The vendor questions this site covers sit on top of a very real, very large licensed market. Public survey data illustrates the scale: a KFF Health Tracking Poll (May 2024) found roughly 1 in 8 U.S. adults (about 12%) reported having ever used a GLP-1 medication, with about 6% currently taking one, and Goldman Sachs Research projected in 2023 that the anti-obesity medication market could reach roughly $100 billion annually by 2030. Demand of that scale, colliding with high list prices and periodic supply shortages, reliably spills into unlicensed channels - which is where vendor names like Nexaph circulate.
The published science behind the compounds most discussed in that overflow market, summarized from the primary journal publications:
| Compound | Trial (publication) | Duration | Dose | Mean weight change |
|---|---|---|---|---|
| Semaglutide | STEP 1, NEJM 2021 (n=1,961) | 68 weeks | 2.4 mg weekly | −14.9% vs −2.4% placebo |
| Tirzepatide | SURMOUNT-1, NEJM 2022 (n=2,539) | 72 weeks | 5 / 10 / 15 mg weekly | −15.0% / −19.5% / −20.9% vs −3.1% placebo |
| Retatrutide | Phase 2, NEJM 2023 (n=338) | 48 weeks | up to 12 mg weekly | −24.2% at the highest dose (Phase 2; investigational) |
Three cautions apply whenever this table is quoted anywhere online. These are supervised trial results in screened populations with structured dosing - not descriptions of self-sourced use. The retatrutide figure is Phase 2 evidence from a 338-participant trial, against Phase 3 programs several times larger for the approved comparators. And none of these numbers carry over to material of unverified identity - the core product-quality problem of the grey market our coverage documents.
Where each compound stands with regulators:
| Compound | Receptor targets | Approx. half-life | Schedule | Regulatory status |
|---|---|---|---|---|
| Liraglutide | GLP-1 | ~13 hours | Daily injection | Approved for obesity (as Saxenda) |
| Semaglutide | GLP-1 | ~1 week | Weekly injection | Approved for obesity (Wegovy) and T2D |
| Tirzepatide | GIP + GLP-1 | ~5 days | Weekly injection | Approved for obesity (Zepbound) and T2D |
| Retatrutide | GIP + GLP-1 + glucagon | ~6 days | Weekly in trials | Investigational - not approved in any jurisdiction |
Our Evidence Hierarchy
Every claim on this site is sorted into a fixed hierarchy of evidence before it is published. This is the single most useful idea on the site, because it applies to every other page you will ever read about grey-market vendors:
| Evidence tier | Example | Reliability | How we use it |
|---|---|---|---|
| Peer-reviewed clinical trials | NEJM, Lancet publications | Highest | Cited directly, with trial name and sample size |
| Regulator publications | FDA, MHRA, EMA statements and approvals | High | Cited directly |
| Named third-party lab reports | Independent analytical lab COAs | Medium (verifiable only with the lab) | We report their existence, not their conclusions as fact |
| Public community discussion | Reddit threads, Telegram posts | Low - anecdote | Summarized as patterns, always labeled |
| Anonymous testimonials | Review-site posts | Lowest | Counted, never endorsed or repeated as fact |
Most vendor disputes online are arguments between tier-4 claims - which is why they can never be settled by more testimonials, only by tier-3 documents (verifiable third-party lab reports) or tier-1 data. Full details on the About & Methodology page.
Editorial Standards
- No vendor money. No referral fees, no free products, no sponsored reviews. Revenue, if any, is clearly-labeled advertising only.
- Anecdote is labeled anecdote. Community reports are summarized as reports - never presented as clinical findings or product authentication.
- No fake verdicts. We do not score, rank or certify grey-market vendors, because anonymous sentiment cannot support those claims in either direction.
- Corrections welcome. Public coverage evolves; if something here is outdated or wrong, tell us and we will fix it.
Full details on the About & Methodology page.